How to Register Your Medical Device in China in 2026: Complete NMPA Guide

How to Register Your Medical Device in China in 2026: Complete NMPA Guide

Category: Industry Intelligence (49) → Healthcare (85) • Also filed under: Compliance (13) → Medical (73) • Last updated: July 2026

1. Understanding the NMPA Regulatory Framework

China’s medical device regulatory environment has undergone a profound transformation over the past decade. The National Medical Products Administration (NMPA) — formerly the China Food and Drug Administration (CFDA) — is the central authority governing the registration, manufacturing, and post-market surveillance of all medical devices sold in China. The agency renamed and restructured in 2018, but the term “CFDA” still appears in older guidance documents and international trade publications.

The cornerstone of modern NMPA device regulation is Decree 739, the Regulations on the Supervision and Administration of Medical Devices, which took effect in its revised form on June 1, 2021. This decree superseded earlier versions (State Council Decree 650 of 2014 and Decree 276 of 2000) and introduced significant changes, including a more refined classification catalog, expanded provisions for clinical evaluation exemptions, and stricter post-market surveillance requirements for high-risk devices.

Two additional regulatory instruments are critical for foreign manufacturers:

• Decree 15 — Medical Device Clinical Trial Quality Management Standards (promulgated 2022, effective 2023), which aligns China’s Good Clinical Practice (GCP) requirements for device trials with international standards while introducing China-specific requirements such as the need for trial data from Chinese populations for most Class III devices.
• GB/T 42061-2022 — the Chinese national standard equivalent to ISO 13485:2016. While NMPA accepts ISO 13485 certification as evidence of quality management system compliance, the agency increasingly expects manufacturers to provide a mapping demonstrating equivalency between their ISO 13485 QMS and the specific requirements of GB/T 42061.

Unlike the U.S. FDA or the European Union’s MDR/IVDR frameworks, China’s NMPA registration is a pre-market approval system for Class II and III devices. This means that a manufacturer must obtain NMPA marketing authorization before any commercial sale or distribution can take place within Chinese territory — including Hong Kong and Macau, which maintain separate but increasingly harmonized regulatory systems (the Hong Kong MDACS and Macau’s ISAF, respectively).

Foreign manufacturers face an additional structural requirement: all NMPA submissions must be filed through a China-based legal representative or a designated Agent. This entity — often a local subsidiary, a contract research organization (CRO), or a regulatory affairs consultancy — is responsible for communication with NMPA, holds the registration certificate, and bears legal liability for post-market compliance. The Agent must be a legally registered Chinese entity; no exceptions are made for foreign companies without a local presence.

2. Device Classification: Class I, II, and III

NMPA classifies medical devices into three categories based on risk level, following the classification catalog last updated in 2024 (the NMPA Medical Device Classification Catalog, revised in partial amendment). Classification determines the entire registration pathway: the review authority, the documentation burden, whether clinical trials are required, and the expected timeline and cost.

The table below summarizes the key differences across the three classes.

The classification decision is not always intuitive. A device that qualifies as Class I in the EU (under MDR Class I) or as a 510(k)-exempt device in the U.S. may be classified as Class II in China. The NMPA Classification Catalog now runs over 1,000 pages and is updated in localized amendments each year. Foreign manufacturers are strongly advised to obtain a binding classification determination from NMPA or a qualified regulatory consultant before committing resources to a registration pathway.

In 2025 the NMPA also introduced a pilot Innovative Medical Device Fast-Track Program, which has accelerated review timelines for breakthrough devices by 30–50%. Devices qualifying under this program — those with novel technology, significant clinical advantage, and Chinese intellectual property claims — can see Class III timelines reduced to 12–18 months.

3. The Step-by-Step NMPA Registration Process

The registration process for Class II and III devices follows a structured pathway. While Class I devices follow a simpler filing procedure (typically submitted online to the provincial bureau with minimal documentation), the process below applies to the more demanding Class II and Class III pathways that concern most foreign manufacturers.

Step 1: Classification Confirmation

Before doing anything else, confirm your device’s classification under the current NMPA Medical Device Classification Catalog (2024 edition with 2025 and 2026 partial amendments). If in doubt, submit a formal classification application to NMPA or retain a recognized third-party classification service. Misclassification is one of the costliest errors a foreign manufacturer can make — a device submitted as Class II that NMPA deems Class III will be rejected outright, wasting months and tens of thousands of renminbi.

Step 2: Engage a China Agent or Legal Representative

Appoint a qualified China-based Agent that will act as your legal representative before NMPA. The Agent must hold a valid business license and have a registered address in mainland China. The Agent’s responsibilities include filing the application, receiving NMPA correspondence, and retaining post-market vigilance obligations for the duration of the registration validity. This relationship must be formalized through a power of attorney (PoA) notarized both in your home country and in China.

Step 3: Quality Management System (QMS) Preparation

Ensure your manufacturing facility operates a QMS certified to ISO 13485:2016. Prepare a mapping document that shows equivalence between each clause of ISO 13485 and the corresponding requirements of GB/T 42061-2022. For Class III devices, NMPA will conduct an on-site QMS audit at your foreign factory. These audits are unannounced in scheduling but typically occur 4–6 months after submission. NMPA auditors examine production lines, sterilization records, complaint handling, and supplier controls against both ISO 13485 and Chinese GMP requirements (the Medical Device Production Quality Management Standards under Decree 739).

Step 4: Compile the Technical Dossier

Prepare the technical documentation according to NMPA’s Medical Device Registration Application Documentation Requirements (announcement No. 2021年第121号, as amended). The dossier must include device description and specifications, design and manufacturing information, risk management file (per YY/T 0316 / ISO 14971), product performance testing reports (from a CNAS-accredited lab where required), biocompatibility evaluation (per GB/T 16886 series / ISO 10993), and clinical evaluation data (see Section 4 for the full list).

Step 5: Submit to NMPA (CMDE for Class II/III)

Submissions are made through the NMPA online portal (eRPS system). The submission fee ranges from approximately RMB 7,500 (Class I) to RMB 85,000 (Class III), though this excludes consulting and testing costs. The application is assigned to a primary reviewer at CMDE who will issue one or more rounds of deficiency questions. The clock stops each time a deficiency notice is issued — the manufacturer’s response time counts against no regulatory timeline, which is why average total duration often exceeds the nominal review window.

Step 6: Technical Review and Deficiency Response

CMDE’s technical review cycle for Class II devices is nominally 80 working days; for Class III, it is 120 working days. However, the clock pauses for each deficiency round. Most Class III applications go through 2–4 rounds of deficiency inquiries. The key to expediting this phase is submitting a complete, well-translated dossier on the first attempt — each round adds 2–4 months to the timeline.

Step 7: QMS Audit and On-Site Inspection (Class II/III)

For Class III devices and selected Class II devices, NMPA arranges an on-site QMS inspection at the manufacturing facility. For foreign manufacturers, this means a visit by NMPA-appointed inspectors to your overseas factory. The inspection typically lasts 2–4 days and follows a detailed checklist aligned with the Medical Device Production Quality Management Standards. Inspectors will review your QMS documentation in detail, walk production lines, interview quality personnel, and may collect product samples for testing. Failed inspections require remediation and re-inspection, adding 6–12 months.

Step 8: Approval and Certificate Issuance

Once the technical review and QMS inspection are both cleared, NMPA issues the Medical Device Registration Certificate. For Class II and III devices, the certificate is valid for five years and must be renewed within six months of expiry. Upon issuance, the device is formally authorized for import, distribution, and sale across mainland China.

Step 9: Post-Market Compliance

Registration is not the finish line — it is the starting point for post-market obligations. These include adverse event reporting (within 20 days for serious events), periodic risk assessment reports (annually for Class III, every two years for Class II), field safety corrective actions (FSCA) when required, and renewal applications. NMPA conducts routine and for-cause inspections of registered products and their manufacturers throughout the five-year validity period.

The following Quick-Reference Checklist summarizes the critical milestones for foreign manufacturers:

1. Confirm device classification under the latest NMPA Classification Catalog (2024–2026 amendments).
2. Appoint a qualified China-based Agent with a valid business license and PoA.
3. Certify QMS to ISO 13485 and prepare GB/T 42061 equivalency mapping.
4. Engage a CNAS-accredited testing lab for product performance and biocompatibility testing.
5. Compile full technical dossier — Chinese translation mandatory for all regulatory submission documents.
6. Submit eRPS application via NMPA online portal with fee payment.
7. Respond to CMDE deficiency inquiries within the specified deadline (typically 60–90 days).
8. Prepare for on-site QMS inspection (mandatory for Class III, risk-based for Class II).
9. Receive Registration Certificate and begin commercial importation.
10. Establish post-market surveillance systems including adverse event reporting and renewal calendar.

4. Required Documentation for NMPA Submission

The NMPA technical dossier is comprehensive and must be submitted in Chinese. Translations must be notarized or certified. The following documents are required for a standard Class II or III device registration:

• Application Form — NMPA-prescribed format, signed by the legal representative (or China Agent with PoA).
• Power of Attorney (PoA) — Notarized in the manufacturer’s home country and legalized for use in China (apostille or consular legalization as applicable).
• Device Description and Specifications — Including working principles, intended use, key performance parameters, and diagrams.
• Design and Manufacturing Information — Process flow diagrams, material specifications, sterilization validation, and packaging details.
• Risk Management File — Per ISO 14971:2019 / YY/T 0316, including hazard identification, risk estimation, and residual risk evaluation.
• Product Performance Testing Reports — From a CNAS-accredited testing laboratory. For electrical medical devices, a Chinese GB 9706.1 (IEC 60601-1 equivalent) testing report is mandatory.
• Biocompatibility Evaluation Report — Per GB/T 16886 series (ISO 10993), covering cytotoxicity, sensitization, irritation, acute systemic toxicity, hemocompatibility, and implantation where applicable.
• Clinical Evaluation Data — This can take one of three forms: (a) a full clinical trial report conducted in China or accepted under the foreign data pathway; (b) a clinical evaluation report (CER) with literature review and equivalence analysis; or (c) an exemption declaration if the device appears on NMPA’s Clinical Evaluation Exemption Catalog.
• Labeling and Instructions for Use (IFU) — Chinese-language labels and user manuals; English versions may be submitted as supplementary references. Labeling must comply with the Medical Device Labeling and Instructions for Use Regulations (Decree 739, Chapter 5).
• Quality Management System Certificates — ISO 13485 certificate (valid, with scope covering the registered device) plus GB/T 42061 equivalency mapping.
• Manufacturing Authorization Documents — Business license, manufacturing license (or equivalent from the home country regulatory authority), and free sale certificate demonstrating that the device is legally marketed in the country of origin.
• Stability and Shelf-Life Data — Accelerated and real-time aging studies demonstrating device stability and packaging integrity over the declared shelf life.
• Software Description (for software as a medical device / SaMD) — Software architecture, algorithm validation, cybersecurity risk assessment per NMPA’s 2022 SaMD guidance.

Missing any one of these documents can trigger a formal deficiency notice that pauses the review clock. Incomplete dossiers — particularly those lacking adequate clinical evaluation data or CNAS-accredited test reports — account for an estimated 40% of initial rejection decisions, according to industry analysis published in Regulatory Rapporteur (January 2026).

5. Timelines and Costs by Classification

One of the most frequent surprises for first-time applicants is the gap between NMPA’s nominal review timelines and the real-world duration, which includes external testing, translation, QMS readiness, and deficiency response cycles. The table below provides realistic ranges based on 2025–2026 market data.

Note that the costs above do not include entity setup fees for establishing a Wholly Foreign-Owned Enterprise (WFOE) in China, which many foreign manufacturers choose as their Agent structure. A WFOE setup typically adds RMB 50,000–150,000 and 2–4 months to the preliminary timeline. However, a WFOE offers significant operational advantages over a third-party Agent arrangement, including direct control over importation, distribution, and after-sales service.

According to the 2025 China Medical Device Registration Annual Report published by the China Center for Food and Drug International Exchange (CCFDIE), the median Class III review time from formal acceptance to approval has declined from 28 months (2020) to approximately 22 months (2025), as NMPA has invested in reviewer recruitment, digitalization of the eRPS system, and the fast-track innovation pathway.

6. Common Registration Pitfalls and How to Avoid Them

Based on NMPA deficiency statistics and interviews with regulatory consultants active in the China market, the following pitfalls account for the majority of registration delays and rejections for foreign manufacturers.

6.1 Insufficient Clinical Evaluation Data

The single most common reason for deficiency notices is inadequate clinical evidence. Foreign manufacturers often assume that CE MDR or FDA clearance data will suffice, but NMPA reviewers apply their own standards for clinical evaluation. Even devices on the NMPA Clinical Evaluation Exemption Catalog (which covers many Class I and some Class II devices) require a documented exemption rationale. For Class III devices that require clinical data, NMPA expects that at least a portion of the data comes from the Chinese population, unless a robust scientific justification demonstrates that ethnicity-based differences in safety or efficacy are unlikely. Solution: Budget for a China-specific clinical bridging study or a comprehensive CER that addresses NMPA’s unique requirements from the outset.

6.2 QMS Non-Compliance During On-Site Inspection

Foreign manufacturers that pass ISO 13485 certification audits routinely fail NMPA’s on-site inspections. The gap lies in Chinese GMP requirements that go beyond ISO 13485, including specific requirements for cleanliness of production areas (GB 50457-2019), sterile barrier validation per Chinese standards, and unique record-keeping formats. Solution: Conduct a gap analysis between your existing QMS and the Medical Device Production Quality Management Standards (announcement No. 2022年第59号) before the inspection. Consider hiring a Chinese QMS consultant experienced with NMPA audits. As one industry source told MedTech Insight (June 2025), “The companies that pass on the first try are the ones that run mock inspections with an NMPA-trained auditor six months before the real visit.”

6.3 Labeling and IFU Non-Conformance

Chinese labeling regulations under Decree 739 are detailed and prescriptive. Common non-conformances include missing Chinese-language cautions, incorrect formatting of registration certificate numbers, absence of the China Agent’s contact information on the label, and failure to list all accessories and consumables. Solution: Have your Chinese translation and labeling reviewed by a native-speaking regulatory professional before submission.

6.4 Incomplete or Poorly Translated Dossiers

NMPA requires all regulatory submission documents in Chinese. Machine translation or freelance translators without medical device regulatory experience produce errors that lead to deficiency inquiries. Technical terms, units of measurement, and performance specifications must be translated precisely according to NMPA’s accepted terminology. Solution: Use a translation agency specializing in medical device regulatory submissions with native-speaking technical translators and a review process that includes a regulatory professional’s sign-off.

6.5 Failure to Monitor Catalog Updates

The NMPA Classification Catalog is updated in partial amendments multiple times per year. A device that was classified as Class II at the start of your project may be reclassified as Class III during the process, dramatically changing your timeline and cost. Solution: Work with a regulatory partner who actively monitors NMPA announcements and can alert you to classification changes before you submit.

6.6 Underestimating Post-Market Obligations

Many foreign manufacturers successfully obtain registration only to face compliance challenges after market entry. NMPA’s post-market surveillance requirements include adverse event reporting within 20 days, annual or biennial risk assessment reports, and pass-through inspections. Failure to comply can result in suspension of the registration certificate. Solution: Designate a post-market compliance officer (or outsource to your Agent) before the registration is issued. The cost of post-market compliance runs approximately RMB 50,000–100,000 per year for a typical Class II or III device.

“Foreign companies often view NMPA registration as a one-time hurdle. In reality, it is the beginning of an ongoing regulatory relationship. The companies that succeed in China long-term are those that treat regulatory compliance as a continuous investment, not a checkbox exercise.”

— Director of Regulatory Affairs, European MedTech Association (interviewed Q1 2026)

7. Where to Go From Here

Registering a medical device with China’s NMPA is a complex but navigable process. The key success factors are: start early, classify correctly, budget realistically, invest in quality translation and testing, and treat post-market compliance as a long-term commitment. The Chinese medical device market continues to grow at 8–10% annually and offers substantial opportunities for foreign manufacturers that invest in proper market access.

For further reading and actionable next steps, explore the following resources on china-gateway360.com:

• Understanding China’s Medical Device Classification Catalog: A Practical Guide for Importers — Deep dive into the 22-subcategory classification system with real-world examples of devices that are commonly misclassified.
• Setting Up a Wholly Foreign-Owned Enterprise (WFOE) for Medical Device Importation — Step-by-step walkthrough of entity formation, capital requirements, and the business license categories needed to import and distribute registered medical devices.
• NMPA On-Site QMS Inspection: A Foreign Manufacturer’s Preparation Checklist — Detailed guidance on what NMPA inspectors look for, common findings, and how to conduct a mock audit that identifies gaps before the official visit.

If you found this guide valuable, you may also want to review our China Medical Device Import Tariffs and Customs Clearance Guide 2026 and our Comparative Analysis: NMPA vs. FDA vs. EU MDR Registration Requirements, both available in the Healthcare section of china-gateway360.com.

Sources and Further Reading:

1. National Medical Products Administration (NMPA), Medical Device Registration Application Documentation Requirements, Announcement No. 2021年第121号.
2. State Council of the People’s Republic of China, Regulations on the Supervision and Administration of Medical Devices (Decree 739), revised 2021.
3. China Center for Food and Drug International Exchange (CCFDIE), 2025 China Medical Device Registration Annual Report.
4. NMPA, Medical Device Clinical Trial Quality Management Standards (Decree 15), effective 2023.
5. Regulatory Rapporteur, “NMPA Registration Trends for Foreign Medical Device Manufacturers,” January 2026.
6. MedTech Insight, “QMS Inspection Insights: Why ISO 13485 Isn’t Enough for NMPA,” June 2025.

How to Register Your Medical Device in China in 2026: Complete NMPA Guide — first published on China Gateway 360. Last updated: July 2026.